Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kämpfe D, Schmoll HJ, Súbert R, Kubel M, Niederwieser D, Helbig W; East German Hematology and Oncology Group (OSHO).
Mantovani L, et al. Among authors: schmoll hj.
Leuk Lymphoma. 2002 Feb;43(2):265-74. doi: 10.1080/10428190290006035.
Leuk Lymphoma. 2002.
PMID: 11999557
Clinical Trial.